grant
Anti-Xist RNP antibodies (AXA) in autoimmune disease diagnosis and prognosis
Organization STANFORD UNIVERSITYLocation STANFORD, UNITED STATESPosted 1 Sept 2025Deadline 31 May 2030
NIHUS FederalResearch GrantFY20253-D3-Dimensional3DAddressAffectAmericanAnti-Rejection TherapyAnti-SmithAntibodiesAntigenic DeterminantsAntinuclear AntibodiesAntinuclear FactorsAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmune StatusAutoimmunityAutologous AntigensBinding DeterminantsBirthBlind SpotsBloodBlood Reticuloendothelial SystemCOBRECell LineCellLineCenter of Biomedical Research ExcellenceCenters of Research ExcellenceClinicalComplexCustomCutaneousDataDeath RateDermatomyositisDermatopolymyositisDetectionDevelopmentDiagnosisDiagnosticDifferences between sexesDiffers between sexesDiffuseDiseaseDisease ManagementDisease stratificationDisorderDisorder ManagementDisproportionate number of femalesDisproportionate number of womenDisproportionately affects femalesDisproportionately affects womenDisproportionately impacts femalesDisproportionately impacts womenDisproportionately in femalesDisproportionately in womenEarly DiagnosisEpitopesFemaleGender BiasGeneral PopulationGeneral PublicHeterogeneityHistoryImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunosuppressive TherapyInterferon Type IKnowledgeLassoLung Tissue FibrosisLupus Erythematosus DisseminatusMapsModelingMusculoskeletal Pain DisorderNon-Polyadenylated RNAOrganOutcomeP50 MechanismP50 ProgramParturitionPatientsPatternPolymyositis-DermatomyositisPrediction of Response to TherapyPredictive ValueProtein ArrayProteinsPulmonary FibrosisRNARNA Gene ProductsRaynaud DiseaseRaynaud PhenomenonRaynaud SyndromeRecording of previous eventsRegression AnalysesRegression AnalysisRegression DiagnosticsRetinal blind spotRheumatic DiseasesRheumatismRheumatologic DiseasesRheumatologic DisorderRibonucleic AcidRibonucleoproteinsRoleSLESYS-TXSamplingSclerodermaSelf-AntigensSeveritiesSeverity of illnessSex BiasSex DifferencesSexual differencesSpecialized CenterStandardizationStatistical RegressionStrains Cell LinesStructureSystemic Lupus ErythematosusSystemic Lupus ErythematousSystemic Lupus ErythmatosusSystemic SclerodermaSystemic SclerosisSystemic TherapyTestingTherapeutic InterventionTherapeutic immunosuppressionVascular DiseasesVascular DisorderWomanWomen's prevalenceadaptive immunityanti-DNA autoantibodyanti-SmantiDNA autoantibodyantibody based detectionantibody detectionantinuclear autoantibodyartificial immunosuppressionautoimmune antibodyautoimmune conditionautoimmune disorderautoimmunity diseaseautoreactive antibodyblood vessel disorderclinical predictorsclinical subtypescultured cell linecustomscutaneous fibrosisdermal fibrosisdermatosclerosisdetect antibodiesdevelopmentaldiagnostic tooldisease classificationdisease diagnosisdisease prognosisdisease prognosticationdisease severitydisease subgroupsdisease subtypedisorder classificationdisorder subtypedisseminated lupus erythematosusearly detectionearly onseteffective therapyeffective treatmentfemale biasfemale patientsfemale predominancefemale preponderancefemale prevalencefibrosis in the lungfibrotic skingastrointestinalgender assignedhistoriesimmune suppressionimmune suppressive activityimmune suppressive functionimmunosuppression therapyimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimprovedintervention therapylung fibrosismalemortality ratemortality ratiomycophenolate mofetilmycophenolic acid morpholinoethyl esternew diagnosticsnext generation diagnosticsnosologynovelnovel diagnosticspatients being femalepatients being womenpatients who are femalepredict therapeutic responsepredict therapy responsepredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpredominance in femalespredominance in womenprevalence among femalesprevalence among womenprevalence in femalesprevalence in womenprevalent among femalesprevalent among womenprevalent in femalesprevalent in womenprognosticprognostic abilityprognostic powerprognostic significanceprognostic utilityprognostic valueprognosticationprogressive systemic sclerosisresponders and non-respondersresponders from non-respondersresponders or non-respondersresponders versus non-respondersresponders vs non-respondersresponders/nonrespondersresponseself reactive antibodysexsex assignedsex based differencessex-dependent differencessex-related differencessex-specific differencesskin fibrosissocial rolesystemic lupus erythematosistherapy predictionthree dimensionaltraittranslational opportunitiestranslational potentialtreatment predictiontreatment response predictionvascular dysfunctionvasculopathywomen patientswomen's predominancewomen's preponderance♀♂
Description preview
Project Summary
Substantial heterogeneity within autoimmune diseases and overlapping traits across diseases
have limited our ability to tailor effective therapies and sensitive diagnostics specific to each
autoimmune disease. Systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and
dermatomyositis (DM) are three autoimmune diseases with a…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click